

# FORM 7

## MONTHLY PROGRESS REPORT

Name of Listed Issuer: AREV Life Sciences Global Corp. ("AREV" or the "Issuer").

Trading Symbol: AREV

Number of Outstanding Listed Securities: 31,762,368

Date: January 2023

### Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

AREV is an early-stage life science discovery enterprise dedicated to delivering solutions to public health through discovery, collaborations in the life science industry, and pathogen remediation. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition including the late-stage development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of chronic infection. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECCanada and The Biotechnology Innovation Organization (BIO).

2. Provide a general overview and discussion of the activities of management.

During the month of January 2023 the Company was please to announce the outcome of the votes at the annual meetings of the shareholders of AREV held on January 4, 2022 in Vancouver, British Columbia.

On January 4, 2023, AREV held its Annual General Meeting; the results follow:

#### Item 1: Number of Directors

The number of Directors was set to the election of six (6); this item was passed by ordinary resolution.

#### Item 2: Election of Directors

The six (6) nominees set forth in the November 21, 2022 management information circular of the Company (Mike Withrow, Denby Greenslade, Melvin Maxwell, Allan Echino, Brian Elliott and Kevin Phelps) were elected as Directors of the Company through adoption an ordinary resolution.

#### Item 3: Appointment of Auditors

MNP LLP (formerly Harbourside CPA LLP) was appointed as the "Auditors of the Corporation" for the ensuring year, and the Directors were authorized to fix the auditors' remuneration, all approved by the shareholders through act of an ordinary resolution.

#### Item 4: Approval of Incentive Stock Option Plan

The proposed Stock Option Plan, to which the Directors are now authorized to make modifications, in accordance with the Stock Option Plan and policies of the Canadian Securities Exchange, was passed by ordinary resolution.

During the month of January 2023 the Company announced the resignation of Melvin Maxwell.

The Company announces the resignation of Mr. Melvin Maxwell. The Company would like to thank Mr. Maxwell for his efforts on behalf of the Company and wish him well in his future endeavors.

During the month of January 2023 the Company was pleased to announce that the Company has issued 200,000 stock options to Directors, Officers and Consultants of the Company at a price of \$0.165 for a period of 5 years from the issuance dated. These options will vest immediately.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**NONE.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**NONE.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**NONE.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**NONE.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**NONE.**

8. Describe the acquisition of new customers or loss of customers.

**NONE.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**NONE.**

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

**NONE.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**NONE.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

In the Provincial Court of British Columbia (Small Claims Court), the Company is the defendant against claimant Moody's Private Client LLP in the amount of \$11,982.70.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**NONE.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Stock Options	200,000	Stock option grant at \$0.165 to Voelpel Gold Medal Investments	n/a

## FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 2

Common Shares	125,000	Stock option exercise at \$0.12	General Working Capital
Common Shares	100,000	Stock option exercise at \$0.165	General Working Capital

(1) *State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.  
n/a.

16. Provide details of any changes in directors, officers or committee members.

**Melvin Maxwell resigned from the Board of Directors on January 9, 2023.**

17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's financial statements (the "YE Financial Statements") and corresponding management's discussion and analysis (the "YE MD&A") for the year-ended December 31, 2021. The Q4 Financial Statements and YE MD&A are both available under the Issuer's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

## Certificate Of Compliance


The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 8, 2023.

Mike Withrow

Name of Director or Senior Officer



Signature

CEO & Director

Official Capacity

<b>Issuer Details</b>		For Month End	Date of Report
Name of Issuer AREV Life Sciences Global Corp.		January 2023	YYYY/MM/DD 2023/02/08
Issuer Address Unit 18 – 91 Golden Drive			
City/Province/Postal Code Coquitlam, BC, V3K 6R2	Issuer Fax No. ( ) n/a	Issuer Telephone No. (604) 803-8439	
Contact Name Denby Greenslade	Contact Position Corporate Secretary	Contact Telephone No. (604) 803-8439	
Contact Email Address denby@arevlifesciences.com	Web Site Address www.arevlifesciences.com		